Vafidemstat, a selective LSD1 inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A), which is currently being investigated for its potential antipsychotic and pro-cognitive effects, may enhance neuroplasticity, reduce microglial activation, and normalize excessive synaptic pruning, particularly in the early stages of psychosis. This evidence concerns the gene KDM1A and psychotic disorder.